Treatments
|
Dose (mg/kg)
|
Brain lipid peroxidation, MDA (nmol/g-wet tissue)
|
Brain reduced glutathione, GSH (μg/g-wet tissue)
|
Brain GABA level (μg/g-wet tissue)
|
---|
Vehicle + Saline
|
– + –
|
142.79 ± 16.24
|
196.24 ± 12.31
|
398.51 ± 12.42
|
Vehicle + PTZ
|
– + 30
|
454.62 ± 18.41
|
101.17 ± 14.24
|
297.38 ± 13.59
|
IGEFA + PTZ
|
15 + 30
|
362.24 ± 16.26*
|
132.15 ± 13.15*
|
398.53 ± 18.37
|
IGEFA + PTZ
|
30 + 30
|
195.13 ± 19.15**
|
158.47 ± 12.41*
|
397.62 ± 13.85
|
IGEFA + PTZ
|
60 + 30
|
178.47 ± 17.39**
|
185.75 ± 14.53**
|
435.49 ± 17.52*
|
IGEFA + PTZ
|
90 + 30
|
156.19 ± 16.43***
|
192.25 ± 16.24**
|
455.13 ± 16.38**
|
SVA + PTZ
|
300 + 30
|
149.17 ± 19.75***
|
195.62 ± 14.46**
|
452.36 ± 15.46**
|
SVA + Saline
|
300 + –
|
147.36 ± 17.15***
|
197.37 ± 19.31**
|
462.37 ± 17.25**
|
IGEFA + Saline
|
90 + –
|
152.61 ± 17.35***
|
199.21 ± 14.19**
|
471.41 ± 14.33**
|
- Results are expressed as mean ± S.E.M., for 6 animals. Data were analysis by two-way ANOVA, followed by Newman-Keuls post hoc test
-
MDA malondialdehyde, GSH glutathione, GABA gamma-aminobutyric acid, SVA sodium valproate, IGEFA iridoid glycosides extracts of Feretia apodenthera
- *P < 0.05, **P < 0.01, ***P < 0.001, significantly different compared to the vehicle-treated PTZ mice